SLC5A2 and type 2 diabetes mellitus: Initially employed as an approach to lower glucose in type 2 diabetics, sodium‐glucose cotransporter‐2 (SGLT‐2) inhibitors have demonstrated consistent beneficial effects in humans with heart failure independent of diabetes, and in mitigating the progression of renal disease.1, 2, 3